Savara Inc (SVRA)

Trade SVRA now with
9/18/2018 7:00:36 AM BioTime Implements New Leadership Structure; Appoints Brian Culley As CEO
8/9/2018 4:05:17 PM Savara Q2 Loss Per Share Of $0.38 Vs. $0.90 Last Year
7/26/2018 9:17:37 AM Savara Prices Public Offering Of 4.25 Mln Shares At $11.50 Per Share
7/25/2018 4:28:37 PM Savara Announces Proposed Public Offering Of Common Stock
5/29/2018 8:08:18 AM Savara Update On Case Reports Of Inhaled Granulocyte-Macrophage Colony Stimulating Factor For Treatment Of NTM
3/13/2018 8:04:32 AM Savara Initiates Phase 2a Study Of Molgradex For Treatment Of NTM Lung Infection
3/11/2018 11:24:05 AM Aironite Fails To Meet Primary Endpoint In Indie Phase 2 Study Conducted By Heart Failure Clinical Research Network
2/16/2018 8:17:22 AM Savara To Present Top Line Results From Aironite Phase 2 Clinical Trial For Treatment Of HFpEF
12/21/2017 8:43:47 PM Savara Announces Submission Of IND Application To FDA For Its Lead Product Molgradex
10/25/2017 9:39:35 AM Savara Announces Pricing Of Public Offering Of 5.25 Mln Shares At $7.85/shr
10/18/2017 8:05:47 AM Savara Completes Enrollment In Phase 2 Clinical Trial Of Aironite For Treatment Of HFpEF
9/26/2017 8:03:03 AM Savara Announces Start Of Pivotal Phase III AVAIL Study Of AeroVanc
8/9/2017 8:14:45 AM Savara Q2 Net Loss Attributable To Common Shareholders $12.5 Mln Or $0.90/Shr
6/29/2017 6:01:22 AM Hercules Capital Announces Addl Portfolio Company Liquidity Events; Portfolio Companies Currently In IPO Registration